Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease
- Resource Type
- Source
- American Journal of Respiratory and Critical Care Medicine
American Journal of Respiratory and Critical Care Medicine, 2021, 204 (1), pp.64-73. ⟨10.1164/rccm.202011-4153OC⟩ - Subject
Lung Diseases Male elexacaftor Indoles Cystic Fibrosis Pyridines medicine.medical_treatment Regulator Aminophenols Critical Care and Intensive Care Medicine [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract Cystic fibrosis Gastroenterology Membrane Potentials Ivacaftor 0302 clinical medicine Prospective Studies 030212 general & internal medicine Chloride Channel Agonists Aged, 80 and over Middle Aged Transmembrane protein Drug Combinations Quinolines Female France medicine.drug Adult Pulmonary and Respiratory Medicine congenital, hereditary, and neonatal diseases and abnormalities medicine.medical_specialty cystic fibrosis transmembrane conductance regulator modulators Adolescent Pulmonary disease Young Adult 03 medical and health sciences Internal medicine lung transplantation medicine Humans Lung transplantation In patient Aged [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics business.industry Editorials medicine.disease 030228 respiratory system Tezacaftor Pyrazoles business - Language
- ISSN
- 1535-4970
1073-449X